Dr. Frank is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
40 Cross St
Norwalk, CT 06851Phone+1 203-845-4899Fax+1 203-845-4897
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1992 - 1996
- New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1989 - 1992
- Stony Brook University Health Sciences Center School of MedicineClass of 1989
Certifications & Licensure
- CT State Medical License 2000 - 2025
- NY State Medical License 1990 - 2024
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Greenwich Magazine Castle Connolly, 2012-2014
- Top Doctors: New York Metro Area Castle Connolly, 2011-2014
- Westport Magazine Castle Connolly, 2012
- Join now to see all
Clinical Trials
- Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy Start of enrollment: 2001 Sep 01
- Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Start of enrollment: 2005 Mar 01
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 75 citationsPhase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myelomaW. Larry Gluck, Mrinal M. Gounder, Richard Frank, Ferry A.L.M. Eskens, Jean-Yves Blay
Investigational New Drugs. 2020-06-01 - 322 citationsA 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a pr...Craig H. Moskowitz, Stephen D. Nimer, Andrew D. Zelenetz, Tania Trippett, Eric Hedrick
Blood. 2001-02-01 - 109 citationsFunctional and physical interactions between AML1 proteins and an ETS protein, MEF: implications for the pathogenesis of t(8;21)-positive leukemias.Shifeng Mao, Richard C. Frank, Jin Zhang, Yasushi Miyazaki, Stephen D. Nimer
Molecular and Cellular Biology. 1999-05-01
Press Mentions
- Danbury & Norwalk Hospitals in CT Serve as Trial Site for Lung Cancer & Colon Cancer Clinical TrialOctober 27th, 2020
- Hospitals Offer New Clinical Trials for Cancer PatientsOctober 26th, 2020
- NRG Oncology Approves Danbury and Norwalk Hospitals as Primary Sites for Clinical ResearchSeptember 22nd, 2019
- Join now to see all
Grant Support
- AML1/ETO Fusion Protein And LeukemogenesisNational Cancer Institute1996–2000
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: